Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
A cunning culprit that aids cancer cells in avoiding CAR T cell therapy has been identified by researchers at City of Hope®, one of the biggest and most cutting-edge cancer research and treatment organizations in the United States, with a comprehensive cancer center in Los Angeles that is ranked among the top five cancer centers in the country by US News & World Report.
Scientists are literally shining a laser on the energy centers of cancer cells in an attempt to harm these sources of power and cause widespread cancer cell death.
Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice.
Research from the Federal University of Rio de Janeiro (UFRJ) and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB) in Brazil has uncovered a critical mechanism by which mutations in the p53 protein-;a key tumor suppressor known as the "guardian of the genome"-;turn other proteins into cancer-promoting agents
Glioblastomas are highly aggressive, usually incurable brain tumors. If all therapeutic options are exhausted, patients have an average life expectancy of less than two years.
The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.
By super cooling a molecule on the surface of brain cells down to about minus 180 degrees Celsius -; nearly twice as cold as the coldest places in Antarctica -; scientists at Johns Hopkins Medicine say they have determined how a widely-used epilepsy drug works to dampen the excitability of brain cells and help to control, although not cure, seizures.
The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma -; a serious and often fatal brain cancer -; suppresses the immune system so that the tumor can grow unimpeded by the body's defenses.
Cancer cells release a significantly more concentrated level of acid than previously known, forming an "acid wall" that could deter immune cells from attacking tumors, UT Southwestern Medical Center scientists show in a new study.
Targeting two brain tumor-associated proteins-;rather than one-;with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer, according to early results from the first six patients treated in an ongoing Phase I clinical trial led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center.
While physicists continue to argue about whether time is indeed an illusion, as Albert Einstein claimed, biologists have no doubt about its significance for understanding life as a dynamic system.
A study conducted by pre-PhD researcher Pablo S. Valera and recently published in PNAS demonstrates the potential of surface-enhanced Raman spectroscopy (SERS) to explore metabolites secreted by cancer cells in cancer research.
Glioblastoma is one of the most treatment-resistant cancers, with those diagnosed surviving for less than two years.
Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.
A groundbreaking research conducted at Umeå University in Sweden has revealed that the three-dimensional arrangement of DNA can impact the development of aggressive brain cancer, glioblastoma.
In two concurrent projects, scientists at the Karolinska Institutet have played a significant role in producing the most extensive atlases of human brain cells to date.
A new study has unraveled a crucial link between how cancer cells cope with replication stress and the role of Taurine Upregulated Gene 1 (TUG1). By targeting TUG1 with a drug, the researchers were able to control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors such as glioblastomas.
Chemotherapy and radiotherapy aim to destroy cancer cells by inducing DNA double-strand breaks – damage that, once inflicted, usually causes the cells to die. But damage to a cell's genetic material also activates a signaling pathway called IKK/NF-κB that helps prevent cell death, thus limiting the success of these treatments in patients.
Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. Despite treatment, GBM recurrence is inevitable and tends to occur outside surgical margins or in locations remote to the primary tumor, highlighting the central role played by tumor infiltration in this malicious disease.
A potential advancement in the treatment of glioblastoma was noted by Howard Colman, MD, PhD, the Jon M. Huntsman Presidential Professor of Neuro-Oncology and co-leader of the Neurologic Cancers Disease Center and the Experimental Therapeutics CCSG program at Huntsman Cancer Institute, in a recently published manuscript.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.